MedTrace Logo

A Study of Prevalence of HER3 Expression in Non-Small Cell Lung Cancer

NCT05769764 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 225

Last updated 2023-04-10

No results posted yet for this study

Summary

There is currently a lack of published HER3 expression prevalence data among non-small cell lung cancer (NSCLC) patients. The estimation of HER3 expression prevalence in this population using archival tissue samples and the assessment of associated patient characteristics in real world (RW) data will ultimately inform clinical strategy and increase awareness among health care providers (HCPs) and the greater medical community to improve patient care.

Conditions

Interventions

OTHER

Archival tissue specimen and immunohistochemistry staining

This is a non-interventional study and no intervention will be administered.

Sponsors & Collaborators

Principal Investigators

  • Clinical Leader · Daiichi Sankyo

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-19
Primary Completion
2023-04-06
Completion
2023-04-06

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05769764 on ClinicalTrials.gov